MedKoo Cat#: 527044 | Name: Cefquinome Sulfate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefquinome Sulfate is a broad-spectrum fourth-generation cephalosporin antibiotic.

Chemical Structure

Cefquinome Sulfate
CAS#118443-89-3 (sulfate)

Theoretical Analysis

MedKoo Cat#: 527044

Name: Cefquinome Sulfate

CAS#: 118443-89-3 (sulfate)

Chemical Formula: C23H26N6O9S3

Exact Mass: 0.0000

Molecular Weight: 626.67

Elemental Analysis: C, 44.08; H, 4.18; N, 13.41; O, 22.98; S, 15.35

Price and Availability

Size Price Availability Quantity
250mg USD 400.00 2 Weeks
500mg USD 650.00 2 Weeks
1g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Cefquinome Sulfate
IUPAC/Chemical Name
(6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrogensulfate
InChi Key
KYOHRXSGUROPGY-OFNLCGNNSA-N
InChi Code
InChI=1S/C23H24N6O5S2.H2O4S/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28;1-5(2,3)4/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33);(H2,1,2,3,4)/b27-16-;/t17-,21-;/m1./s1
SMILES Code
O=C(C(N12)=C(C[N+]3=C4CCCCC4=CC=C3)CS[C@]2([H])[C@H](NC(/C(C5=CSC(N)=N5)=N\OC)=O)C1=O)O.[O-]S(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 626.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu C, Han M, Wang H, Chen X, Tang Y, Zhang D, Li X, Liu Y. Elimination of Cefquinome Sulfate Residue in Cow's Milk after Intrauterine Infusion. Metabolites. 2023 Mar 29;13(4):492. doi: 10.3390/metabo13040492. PMID: 37110151; PMCID: PMC10146028. 2: El-Tahawy AO, Said AA, Shams GA, Hassan HM, Hassan AM, Amer SA, El-Nabtity SM. Evaluation of cefquinome's efficacy in controlling avian colibacillosis and detection of its residues using high performance liquid chromatography (HPLC). Saudi J Biol Sci. 2022 May;29(5):3502-3510. doi: 10.1016/j.sjbs.2022.02.029. Epub 2022 Feb 25. PMID: 35844377; PMCID: PMC9280232. 3: Durna Corum D, Corum O, Terzi E, Coskun D, Bilen S, Cetin G, Uney K. Pharmacokinetics of cefquinome in rainbow trout (Oncorhynchus mykiss) after intravascular, intraperitoneal, and oral administrations. J Vet Pharmacol Ther. 2022 Nov;45(6):578-583. doi: 10.1111/jvp.13091. Epub 2022 Aug 24. PMID: 36000461. 4: Rutjens S, Vereecke N, De Spiegelaere W, Croubels S, Devreese M. Intestinal Exposure to Ceftiofur and Cefquinome after Intramuscular Treatment and the Impact of Ceftiofur on the Pig Fecal Microbiome and Resistome. Antibiotics (Basel). 2022 Mar 4;11(3):342. doi: 10.3390/antibiotics11030342. PMID: 35326805; PMCID: PMC8944603. 5: Xiao X, Chen X, Yan K, Jiang L, Li R, Liu Y, Wang M, Wang Z. PK/PD integration and pharmacodynamic cutoff of cefquinome against cow mastitis due to Escherichia coli. J Vet Pharmacol Ther. 2022 Jan;45(1):83-91. doi: 10.1111/jvp.13012. Epub 2021 Sep 1. PMID: 34469000. 6: Yang Q, Zhang C, Liu X, Zhang L, Yong K, Lv Q, Zhang Y, Chen L, Zhong P, Liu Y. The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model. PLoS One. 2023 Jan 25;18(1):e0278306. doi: 10.1371/journal.pone.0278306. PMID: 36696421; PMCID: PMC9876276. 7: Mao Y, Chen Y, Liu C, He X, Zheng Y, Chen X, Wang Y, Chen W, Wu Y, Shen Y, Yang H, Ma S. Cefquinome Sulfate Oily Nanosuspension Designed for Improving its Bioavailability in the Treatment of Veterinary Infections. Int J Nanomedicine. 2022 Jun 2;17:2535-2553. doi: 10.2147/IJN.S348822. PMID: 35677677; PMCID: PMC9169852. 8: Iqbal Z, Hussain HI, Seleem MN, Shabbir MAB, Sattar A, Aqib AI, Kuang X, Ihsan A, Hao H. RNA-seq-based transcriptome analysis of a cefquinome-treated, highly resistant, and virulent MRSA strain. Microb Pathog. 2021 Nov;160:105201. doi: 10.1016/j.micpath.2021.105201. Epub 2021 Sep 20. PMID: 34547409. 9: Rutjens S, Vereecke N, Sauer J, Croubels S, Devreese M. Cefquinome shows a higher impact on the pig gut microbiome and resistome compared to ceftiofur. Vet Res. 2023 Jun 6;54(1):45. doi: 10.1186/s13567-023-01176-8. PMID: 37280708; PMCID: PMC10242799. 10: Mi K, Li M, Sun L, Hou Y, Zhou K, Hao H, Pan Y, Liu Z, Xie C, Huang L. Determination of Susceptibility Breakpoint for Cefquinome against Streptococcus suis in Pigs. Antibiotics (Basel). 2021 Aug 9;10(8):958. doi: 10.3390/antibiotics10080958. PMID: 34439008; PMCID: PMC8389024. 11: Qu S, Dai C, Zhu J, Zhao L, Li Y, Hao Z. Cefquinome-loaded microsphere formulations against Klebsiella pneumonia infection during experimental infections. Drug Deliv. 2018 Nov;25(1):909-915. doi: 10.1080/10717544.2018.1461958. PMID: 29649952; PMCID: PMC6058672. 12: Zhang L, Wu X, Huang Z, Kang Z, Chen Y, Shen X, Cai Q, Ding H. Pharmacokinetic/pharmacodynamic integration of cefquinome against Pasteurella Multocida in a piglet tissue cage model. J Vet Pharmacol Ther. 2019 Jan;42(1):60-66. doi: 10.1111/jvp.12705. Epub 2018 Nov 8. PMID: 30407642. 13: Venkatachalam D, Dumka VK, Ranjan B. Pharmacokinetics of a single intramuscular injection of cefquinome in buffalo calves. J Vet Pharmacol Ther. 2018 Feb;41(1):155-158. doi: 10.1111/jvp.12451. Epub 2017 Sep 11. PMID: 28891215. 14: Cheng P, Feng T, Zhang Y, Li X, Tian L, Wu J, Cheng F, Zeng Y, Chen H, He X, Fu G, Zheng L, Chen H. Comparative pharmacokinetics of intravenous and intramuscular cefquinome sulfate administration in ducklings and goslings. Am J Vet Res. 2020 Nov;81(11):837-877. doi: 10.2460/ajvr.81.11.873. PMID: 33107745. 15: Wang J, Shan Q, Ding H, Liang C, Zeng Z. Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2014 Jun;58(6):3008-12. doi: 10.1128/AAC.01666-13. Epub 2014 Mar 10. PMID: 24614373; PMCID: PMC4068449. 16: Murphy SP, Erwin ME, Jones RN. Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals. Diagn Microbiol Infect Dis. 1994 Sep;20(1):49-55. doi: 10.1016/0732-8893(94)90019-1. PMID: 7867299. 17: Helmschrodt C, Schmidt K, Bertulat S, Klein L, Finnah A, Heuwieser W, Richter A. Quantitative analysis of cefquinome considering different matrix compositions of bovine colostrum and raw milk. Anal Bioanal Chem. 2018 Nov;410(28):7465-7475. doi: 10.1007/s00216-018-1360-8. Epub 2018 Sep 14. PMID: 30218123. 18: Bachmann J, Helmschrodt C, Richter A, Heuwieser W, Bertulat S. Residue concentration of cefquinome after intramammary dry cow therapy and short dry periods. J Dairy Sci. 2018 Aug;101(8):7540-7550. doi: 10.3168/jds.2017-13826. Epub 2018 May 30. PMID: 29859692. 19: Zhou YF, Shi W, Yu Y, Tao MT, Xiong YQ, Sun J, Liu YH. Pharmacokinetic/Pharmacodynamic Correlation of Cefquinome Against Experimental Catheter-Associated Biofilm Infection Due to Staphylococcus aureus. Front Microbiol. 2016 Jan 7;6:1513. doi: 10.3389/fmicb.2015.01513. PMID: 26779167; PMCID: PMC4703793. 20: Zhang L, Yao L, Kang Z, Huang Z, Gu X, Shen X, Ding H. Microdialysis Determination of Cefquinome Pharmacokinetics in Murine Thigh From Healthy, Neutropenic, and Actinobacillus pleuropneumoniae-Infected Mice. Front Pharmacol. 2019 Mar 12;10:249. doi: 10.3389/fphar.2019.00249. PMID: 30914957; PMCID: PMC6422941.